Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management of relapsed and refractory large B-cell lymphoma. However, our understanding of risk factors associated with non-response is still insufficient and the search for predictive biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Voltin, Conrad-Amadeus, Gödel, Philipp, Beckmann, Laura, Heger, Jan-Michel, Kobe, Carsten, Kutsch, Nadine, Borchmann, Peter, Dietlein, Markus, Herrmann, Ken, Stelljes, Matthias, Rahbar, Kambiz, Lenz, Georg, Reinhardt, H. Christian, Teichert, Marcel, Noppeney, Richard, Albring, Jörn C., Seifert, Robert, von Tresckow, Bastian, Flossdorf, Sarah, Hanoun, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829285/
https://www.ncbi.nlm.nih.gov/pubmed/36698613
http://dx.doi.org/10.1097/HS9.0000000000000817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829285/
https://www.ncbi.nlm.nih.gov/pubmed/36698613
http://dx.doi.org/10.1097/HS9.0000000000000817

Ejemplares similares